Report of two novel chromosomal translocations in chronic lymphocytic leukemia

A Athanasiadou1, K Stamatopoulos, A Tsompanakou

  • 1Hematology Department and BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. stavstam@otenet.gr

Leukemia & Lymphoma
|December 29, 2004
PubMed

Insights

Two novel chromosomal translocations were identified in patients with chronic lymphocytic leukemia (CLL). These findings contribute to understanding genetic alterations in CLL progression.

Area of Science:

  • Hematology
  • Cytogenetics
  • Oncology

Background:

  • Chronic lymphocytic leukemia (CLL) is a heterogeneous lymphoid malignancy.
  • Chromosomal abnormalities play a crucial role in CLL pathogenesis and prognosis.
  • Identifying novel genetic alterations can improve our understanding of CLL biology.

Observation:

  • Two distinct cases of CLL presented with novel chromosomal translocations.
  • Case 1 involved a t(9;12)(q12;p11) translocation in a Rai 0/Binet A patient with mutated IgH and Iglambda genes.
  • Case 2 involved an add(10)(q26) and t(13;18)(q14;q21) in a Rai 2/Binet B patient with mutated IgH and unmutated Iglambda genes.

Findings:

  • The identified translocations, t(9;12)(q12;p11) and t(13;18)(q14;q21), are novel in CLL.
  • Breakpoints at 13q14 and 18q21, seen in Case 2, are known to be involved in other CLL aberrations.
  • Aberrations involving 9q12 and 12p11, as in Case 1, are infrequently reported in CLL.

Implications:

  • These novel translocations expand the spectrum of known genetic aberrations in CLL.
  • Further research into these specific translocations may reveal new insights into CLL development and progression.
  • Understanding rare chromosomal abnormalities can refine prognostic models and guide therapeutic strategies in CLL.